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A B S T R A C T
Background: Primary small cell ovarian cancer of pulmonary type (SCCOPT) is a rare aggressive ovarian tumour
with an incidence of< 1%, usually occurring in perimenopausal or postmenopausal women and known to have
a poor prognosis. Current treatment is platinum based but has not resulted in long term survival.
Case presentation: We report a case of a 77-year old Caucasian woman who presented initially with a one-week
history of abdominal discomfort with raised inﬂammatory markers and Ca125 of 50 μ/ml. Calcium levels were
normal. She underwent primary debulking surgery, and histology showed a tumour comprising areas of classical
small-cell carcinoma morphology. 6 cycles of adjuvant chemotherapy with carboplatin was oﬀered. Relapsed/
progressive disease was noted after 3 months of chemotherapy and patient died 7months after treatment
completion.
Conclusions: SCCOPT is a rare aggressive malignancy with majority of the women having an overall survival of
2 years. There is no clear consensus for the diagnosis and optimal treatment.
1. Introduction
Primary ovarian neuroendocrine malignant neoplasms are ex-
tremely rare, accounting for< 2% of all ovarian cancers, and usually
related to the large cell type (Reed et al., 2014). Primary small cell
ovarian cancer was ﬁrst described in 1979 (Reed et al., 2014). It is a
highly aggressive tumour with an incidence rate of< 1% of all ovarian
cancers and a poor outcome (Reed et al., 2014; Eichhorn et al., 1992).
Two tumour variants are described; the small cell cancer of hy-
percalcemic type (SCCOHT) and the pulmonary type (SCCOPT) with
SCCOHT occurring in younger women and SCCOPT in older women
respectively (Reed et al., 2014; Atienza-Amores et al., 2014). They are
not easily distinguished pre-operatively from common epithelial
ovarian cancers and the diﬀerential diagnosis will include germ cell and
granulosa/sex-cord tumors (Reed et al., 2014). To our knowledge, only
22 cases in total of SCCOPT have been described in the literature with
majority of these arising in mature cystic teratomas (Eichhorn et al.,
1992; Rubio et al., 2015; Ikota et al., 2012; Lim et al., 1998; Chang
et al., 1992; Grandjean et al., 2007; Kurasaki et al., 2013; Mebis et al.,
2004; Suzuki et al., 2007; Lo Re et al., 1994; Tsolakidis et al., 2012;
Reckova et al., 2010). However, from these, only 8 cases are described
as “pure” primary SCCOPT (Eichhorn et al., 1992; Kurasaki et al., 2013;
Suzuki et al., 2007; Lo Re et al., 1994; Tsolakidis et al., 2012; Reckova
et al., 2010) (Table 1).
We report a clinical case of unilateral primary SCCOPT presented in
a 77-year old woman, the current treatment options and clin-
icopathological considerations.
2. Case presentation
A 77-year old woman presented to Accident and Emergency with 1-
week history of low abdominal pain, intermittent diﬃculty initiating
micturition and constipation. Clinical examination showed no ascites
and a pelvic mass was found in the pelvis. Ultrasound of the pelvis
demonstrated a 11.7× 9.6× 11.8 cm complex mass in the midline of
the pelvis extending to the right adnexa (Fig. 1). Her blood results were
satisfactory, except for a slight increase in inﬂammatory markers and
Cancer Antigen (CA)-125 of 50 μ/ml, calculating the Risk of Malignancy
Index (RMI) at 450 (Davies et al., 1993).
Hence, Computed tomography (CT) of chest, abdomen and pelvis
was performed which revealed within the pelvic cavity a large
14× 8.2×9.5 cm heterogeneous multi-septated mass with solid and
cystic components originating from the right adnexa and mostly
keeping with ovarian tumour (Fig. 1). There was no evidence of disease
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Table 1
Case reports and clinopathological characteristics of primary ovarian small cell carcinoma of pulmonary type.
Case reports Age (years) FIGO
stage
Origin and
size (cm)
Treatment Postoperative adjuvant treatment Recurrence
(months)
Overall survival
(months)
Case 1: Eichhorn et al.
(1992)
76 IIIB ROV/NA
LOV/NA
STAH, BSO NA NA 12
Case 2: Eichhorn et al.
(1992)
64 IIIB ROV/5.5
LOV/4.5
ΤΑΗ, BSO, OMT,
AP
Cisplatin and cyclophosphamide 8 NA
Case 3: Eichhorn et al.
(1992)
49 IIIB LOV/16 LSO, COL, LYM Cisplatin, cyclophosphamide and doxorubicin NA 13
Lo Re et al. (1994) 16 IIIA LOV/9.5 ΤΑΗ, BSO, OMT Vinblastine, cisplatin, cyclophosphamide,
bleomycin doxorubicin and etoposide
NA 13
Suzuki et al. (2007) 49 IC LOV/15 ΤΑΗ, BSO, OMT,
LYM
Paclitaxel and carboplatin NA ≥36
Reckova et al. (2010) 67 IV ROV/6 ΤΑΗ, BSO, OMT,
AP
Carboplatin and etoposide NA 24
Kurasaki et al. (2013)a 54 IIIA NA ΤΑΗ, BSO, OMT Paclitaxel and carboplatin NA NA
Tsolakidis et al. (2012) 55 IIIC LOV/8 ΤΑΗ, BSO, OMT,
LYM
Carboplatin and etoposide NA ≥21
Current case 77 II ROV/15 ΤΑΗ, BSO, OMT Carboplatin 3 7
NA: Not available; ROV: Right ovary; LOV: left ovary; STAH: Subtotal abdominal hysterectomy; TAH: Total abdominal hysterectomy; BSO: Bilateral salpingoophorectomy; OMT:
Omentectomy; LYM: Lymphadenectomy; AP: Appendicectomy.
a The patient was followed up for 22months without recurrence.
Fig. 1. Imaging ﬁndings: (A) Ultrasound of the pelvis demonstrating a 11.7× 9.6× 11.8 cm complex mass in the midline of the pelvis extending to the right adnexa (B) Abdominal CT
scan demonstrating a 14× 8.2×9.5 cm heterogeneous multi-septated mass with solid and cystic components originating from the right adnexa.
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outside the pelvis with a radiological staging of FIGO stage I and no
evidence of pelvic nor para-aortic lymphadenopathy. The mass was
causing extrinsic compression of the sigmoid colon and the bladder
accounting for her symptoms.
After Multi-Disciplinary Team (MDT) discussion, decision was made
for laparotomy and upfront debulking surgery for suspected ovarian
cancer surgery in a gynaecologic oncology center. At laparotomy, a
15 cm hemorrhagic pelvic mass with mostly solid, friable and necrotic
areas arising from the right ovary was found. It was adherent to the
uterus, bladder, sigmoid, and right pelvic side wall. A thorough as-
sessment of upper abdomen and pelvis showed no evidence of perito-
neal/upper abdominal disease/lymphadenopathy. Total abdominal
hysterectomy, bilateral salpingo-ophorectomy, total omentectomy and
washings was performed, achieving no residual disease and complete
debulking. Intraoperative blood loss was 650ml. Postoperative period
was uneventful apart from a short spell of ileus which resolved with
conservative management. Patient was discharged home in a week.
The ﬁnal pathologic report was discussed at MDT. Histology de-
monstrated a solid hemorrhagic malignant tumour (Fig. 2) comprising
areas of classical small-cell carcinoma morphology, showing cells with
scant cytoplasm, stippled chromatin and nuclear moulding. However,
other areas of the tumour were comprised of spindled cells and epi-
thelioid cells with more abundant cytoplasm. Immunohistochemistry
showed that the lesion was positive with the neuroendocrine markers
CD56 and PGP 9.5, and showed dot-like positivity with the cytokeratin
EMA, including in the spindled and epithelioid components. A ﬁnal
diagnosis of Primary SCCOPT was made and histologically staged as
FIGO stage IC3 but clinical stage II due to the dense adhesions between
the tumour and pelvic structures. A decision for adjuvant chemotherapy
was made at MDT with 6 cycles of Carboplatin and Etoposide and
follow up for the next 5 years (3 monthly for the ﬁrst 3 years and 6
monthly for the next 2 years) as per the hospital ovarian cancer pro-
tocol. Etoposide was omitted from the chemotherapeutic regime in
view of performance status.
3 months following treatment, patient had abdominal discomfort
which triggered a CT scan that conﬁrmed a pelvic relapse. Relapse/
progression of disease soon after treatment indicated a poor prognosis
of survival. Palliative radiotherapy was unlikely to prolong overall
survival and second line chemotherapy with cyclophosphamide, dox-
orubicin and vincristine (VAC) was discussed but declined by the pa-
tient. The patient died 7months after treatment completion.
3. Discussion
SCCOPT is an extremely rare and aggressive ovarian malignancy
(Reed et al., 2014; Rubio et al., 2015). Patients are being aged between
28 and 85 years but most often occurs in perimenopausal and post-
menopausal women with a median age of 59 years (Eichhorn et al.,
1992). Usually it is not seen with hypercalcaemia, and 45% of patients
will have a unilateral involvement (Eichhorn et al., 1992). Tumors size
range from 4.5 to 26 cm (mean 13.5 cm) and are mostly solid, with a
variable minor cystic component (Eichhorn et al., 1992).
Surgical treatment is analogous to that of epithelial ovarian cancers
as there are usually no features to diﬀerentiate SCCOPT form epithelial
ovarian neoplasms. Thereafter, the usual method of clinical examina-
tion, measurement of tumour markers, radiological imaging/staging,
and review at MDT is required (Reed et al., 2014). Patients who are
found to be suitable for primary debulking surgery should be referred to
gynecological oncology center and this should be oﬀered as the treat-
ment of choice (Reed et al., 2014).
There is no clear consensus for the optimal regime for postoperative
chemotherapy because of the small number of patients and unavail-
ability of follow-up data (Eichhorn et al., 1992). In general, adjuvant
chemotherapy with carboplatin and etoposide combination will be of-
fered, which is the commonly used combination chemotherapy used to
treat small cell lung cancer and extrapulmonary uterine and cervical
gynecological small cell cancers (Reed et al., 2014; Eichhorn et al.,
1992). However, there is no supportive evidence that chemotherapeutic
agents are shown to be eﬀective with SCCOPT (Suzuki et al., 2007).
Patients diagnosed with SCCOPT usually have a very poor survival,
generally dying rapidly within 2 years (Reed et al., 2014; Eichhorn
et al., 1992). In the case series by Eichhorn et al., 5 of 7 patients after
long-term follow-up died at 1–13months (mean 8months), 1 died after
an unknown interval, and 1 was alive at 7.5 years. 2 other patients had
recurrent or residual disease at 6 and 8months (Eichhorn et al., 1992).
In the published case reports; it is interesting to note that the overall
survival did not diﬀer between stage 1 and stage 4 indicating its ag-
gressive nature regardless of the staging. Moreover, the older age of
SCCOPT patients and poor performance status may also limit treatment
choices as opposed to SCCOHT, where some successes are occurring
with aggressive and quite toxic multi-drug regimens.
4. Conclusions
SCCOPT is an aggressive malignancy with majority of the patients
dying within 2 years after diagnosis. However, it is interesting to
highlight that the two of the longest survivals seem to be with carbo-
platin and paclitaxel (Suzuki et al. 36months and Kurasaki et al. fol-
lowed up the patient for 22months without recurrence noted). To date,
all treatments so far reported in the literature have been platinum
-based. Upfront surgery should be oﬀered and performed in a gynae-
cologic oncology center. Histologically and immunohistologically, the
tumour cells share features similar to those of pulmonary small cell
carcinoma. To our knowledge, only 8 cases in the literature are de-
scribed as ‘pure’ primary SCCOPT. Given the extreme rarity of this
ovarian carcinoma, more multicenter registries are needed with data
collection in order to understand its behavior and enhance current or
identify new treatment options. Thus, each and every case of SCCOPT if
reported and published in literature could help the gynecological on-
cology society to make appropriate decisions.
Fig. 2. Macroscopic pathology.
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